• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

    5/20/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email

    SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time. 

    Event: William Blair 45th Annual Growth Stock Conference

    Date: Tuesday, June 3, 2025

    Time: 7:20 a.m. PST / 9:20 a.m. CST

    A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

    About CeriBell, Inc.

    Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ("AI")-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

    Investor Contact

    Brian Johnston or Laine Morgan

    Gilmartin Group

    [email protected] 

    Media Contact

    Corrie Rose

    [email protected]



    Primary Logo

    Get the next $CBLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on CeriBell with a new price target

      Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      4/4/25 8:27:23 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BofA Securities initiated coverage on CeriBell with a new price target

      BofA Securities initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

      11/5/24 7:25:17 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Canaccord Genuity initiated coverage on CeriBell with a new price target

      Canaccord Genuity initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

      11/5/24 6:16:50 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Financials

    Live finance-specific insights

    See more
    • Ceribell Reports First Quarter 2025 Financial Results

      SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achieved gross margin of 88% in the first quarter of 2025Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first s

      5/8/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

      SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A li

      4/24/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 25, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing

      2/11/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CeriBell Inc.

      SC 13G - Ceribell, Inc. (0001861107) (Subject)

      11/7/24 9:24:55 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by CeriBell Inc.

      SC 13D - Ceribell, Inc. (0001861107) (Subject)

      10/22/24 4:20:26 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Chao Xingjuan exercised 73,871 shares at a strike of $1.02 and sold $424,000 worth of shares (25,000 units at $16.96), increasing direct ownership by 7% to 776,022 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      5/19/25 12:33:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Chao Xingjuan sold $240,657 worth of shares (15,928 units at $15.11), decreasing direct ownership by 2% to 727,151 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      4/24/25 4:47:39 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Chao Xingjuan sold $136,295 worth of shares (9,072 units at $15.02), decreasing direct ownership by 1% to 743,079 units (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      4/21/25 9:31:10 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

      SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.  Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m. CST A live and archived webcast of the presentation will be available in the "Inv

      5/20/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell Reports First Quarter 2025 Financial Results

      SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achieved gross margin of 88% in the first quarter of 2025Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first s

      5/8/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

      SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.  Event: Bank of America Securities 2025 Health Care ConferenceDate: Wednesday, May 14, 2025Time: 10:55 a.m. PST / 1:55p.m. EST A live and archived webcast of the presentation will be availabl

      4/30/25 4:05:00 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    SEC Filings

    See more
    • SEC Form 144 filed by CeriBell Inc.

      144 - Ceribell, Inc. (0001861107) (Subject)

      5/15/25 10:47:33 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by CeriBell Inc.

      10-Q - Ceribell, Inc. (0001861107) (Filer)

      5/8/25 4:36:43 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ceribell, Inc. (0001861107) (Filer)

      5/8/25 4:13:36 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/17/24 4:14:38 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

      4 - Ceribell, Inc. (0001861107) (Issuer)

      10/16/24 4:18:06 PM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

      —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

      11/19/24 8:00:00 AM ET
      $CBLL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care